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1. INTRODUCTION {#apt15440-sec-0006}
===============

Pancreatic cystic lesions are a common, often incidental finding. Recent large studies using magnetic resonance cholangiopancreatography revealed a remarkably high prevalence in the general population,[1](#apt15440-bib-0001){ref-type="ref"}, [2](#apt15440-bib-0002){ref-type="ref"} of up to 49% and even up to 60% for persons over 70 years.[2](#apt15440-bib-0002){ref-type="ref"} Many of these lesions are neoplastic mucinous cysts, a subgroup with a varying risk of malignant progression, depending on pathological subtype and extent of pancreatic duct involvement.

Of all neoplastic cysts, side branch intraductal papillary mucinous neoplasms (SB‐IPMN) are the most common and deemed to bear the lowest risk of harbouring malignancy or progressing to malignancy. Risk estimations were initially based on small, retrospective series, evaluating mainly resected SB‐IPMN in tertiary referral centres.[3](#apt15440-bib-0003){ref-type="ref"}, [4](#apt15440-bib-0004){ref-type="ref"}, [5](#apt15440-bib-0005){ref-type="ref"}, [6](#apt15440-bib-0006){ref-type="ref"} They reported a risk of invasive carcinoma ranging from 11%[6](#apt15440-bib-0006){ref-type="ref"} to 29%.[3](#apt15440-bib-0003){ref-type="ref"} However, several recent studies indicate a much lower risk for incidentally found SB‐IPMN. In 2015, a meta‐analysis was published including 2177 patients under surveillance for SB‐IPMN, of which only 82 (3.7%) developed a pancreatic malignancy.[7](#apt15440-bib-0007){ref-type="ref"} Since then, several additional studies, each including at least 300 patients with at least 5 years of follow‐up, reported a pancreatic cancer risk of only 0%‐1.6% for small asymptomatic cysts.[2](#apt15440-bib-0002){ref-type="ref"}, [8](#apt15440-bib-0008){ref-type="ref"}, [9](#apt15440-bib-0009){ref-type="ref"}, [10](#apt15440-bib-0010){ref-type="ref"}, [11](#apt15440-bib-0011){ref-type="ref"}, [12](#apt15440-bib-0012){ref-type="ref"} However, all these studies were retrospective and the actual, long‐term risk is yet to be determined by large and prospective studies.

Pending definite answers, the European,[13](#apt15440-bib-0013){ref-type="ref"} AGA,[14](#apt15440-bib-0014){ref-type="ref"} ACG,[15](#apt15440-bib-0015){ref-type="ref"} and international Fukuoka[16](#apt15440-bib-0016){ref-type="ref"} guidelines recommend surveillance with magnetic resonance imaging/magnetic resonance cholangiopancreatography and/or endoscopic ultrasound for all IPMNs, including small unsuspected cysts, in an attempt to detect pancreatic cancer in an early or even premalignant stage. These recommendations pose a considerable burden on patients and health care resources, whereas the clinical benefit with regard to survival remains to be proven.

There are currently no tools to distinguish IPMNs that do not warrant surveillance, or that are helpful in selecting a tailored and optimal surveillance interval. Previous prediction models have focused on identifying high‐risk IPMNs to improve patient selection for surgery.[17](#apt15440-bib-0017){ref-type="ref"}, [18](#apt15440-bib-0018){ref-type="ref"}, [19](#apt15440-bib-0019){ref-type="ref"}, [20](#apt15440-bib-0020){ref-type="ref"}, [21](#apt15440-bib-0021){ref-type="ref"}, [22](#apt15440-bib-0022){ref-type="ref"}, [23](#apt15440-bib-0023){ref-type="ref"}, [24](#apt15440-bib-0024){ref-type="ref"} Although these models are valuable and necessary, the vast majority of SB‐IPMNs do not progress. Therefore, we aimed to develop a prediction model that identifies patients with SB‐IPMN at lowest risk of developing worrisome features or high‐risk stigmata. Such a stratifying tool is needed to prevent redundant surveillance and reduce the burden for patients and health care systems.

2. MATERIALS AND METHODS {#apt15440-sec-0007}
========================

2.1. Study design {#apt15440-sec-0008}
-----------------

We included pancreatic cyst surveillance data from prospectively maintained databases of three academic institutions, namely the Erasmus University Medical Center, Rotterdam, the Netherlands; Columbia University Medical Center, New York, USA; and the Mayo Clinic Florida, Jacksonville, USA. At the Erasmus UMC, the study was exempt from institutional review board review (MEC‐2018‐1285). The study received IRB approval at Columbia UMC (AAAO8260(M01Y04)) and at the Mayo Clinic (14‐007100). The need for written informed consent was waived by the Erasmus UMC and Columbia UMC. At the Mayo Clinic Florida, verbal informed consent was obtained from each participant before enrolment. The study was performed according to the declaration of Helsinki and the manuscript complies with the statement for the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD).[25](#apt15440-bib-0025){ref-type="ref"}

2.2. Participants {#apt15440-sec-0009}
-----------------

The databases contain all consecutive patients under surveillance for a pancreatic cyst since 2004 (Erasmus University Medical Center), 2003 (Columbia University Medical Center), and 2000 (Mayo Clinic Florida). From these databases, we selected patients with a radiologically presumed SB‐IPMN who had been followed‐up for at least 12 months. A subset of these patients have been described previously.[26](#apt15440-bib-0026){ref-type="ref"} We excluded individuals with one or more worrisome features or high‐risk stigmata at baseline, as defined in the 2012 international Fukuoka guidelines[27](#apt15440-bib-0027){ref-type="ref"} (Figure [1](#apt15440-fig-0001){ref-type="fig"}).

![Flow‐chart of patient selection and model development process](APT-50-789-g001){#apt15440-fig-0001}

2.3. Endpoint and candidate predictors {#apt15440-sec-0010}
--------------------------------------

The endpoint was defined as the development of one or more worrisome features or high‐risk stigmata according to the 2012 International Fukuoka guidelines. Candidate predictors were chosen based on prior publications and medical reasoning. Included in the analysis were age, personal history of diabetes mellitus (defined as having a previous diagnosis in electronic medical records), body mass index, ever having smoked personal history of acute pancreatitis, personal history of any type of extrapancreatic malignancy, family history of pancreatic ductal adenocarcinoma, multifocality of the cyst, and the diameter of the largest cyst. All variables were assessed at the time of cyst diagnosis.

2.4. Statistical analysis {#apt15440-sec-0011}
-------------------------

Missing data were imputed using multiple imputation by chained equations (MICE) based on the posterior distributions with five datasets with the MICE package in [r]{.smallcaps} software.[28](#apt15440-bib-0028){ref-type="ref"} We used a Cox‐proportional logistic regression analysis to develop a multivariable prediction model. A linear relation was the best approximation of the relationship between the endpoint and the continuous predictors. A backward stepwise selection procedure was performed with Akaike\'s Information Criterion as stopping rule, to limit overfitting and to prevent exclusion of important predictors. The final model with the best predictive ability was presented with hazard ratios, and 95% CIs calculated using a parametric approach, to indicate the individual predictor effects. The Cox‐proportional hazard assumption was checked and showed nonsignificant results, indicating that proportional hazards can be assumed.

We first performed an internal validation with bootstrap resampling with 500 replications to shrink the model\'s coefficients to minimise overfitting.[29](#apt15440-bib-0029){ref-type="ref"} Subsequently, we performed an internal‐external validation of the final model, in which each subcohort was in turn omitted from the development set and subsequently used as validation set (Figure [1](#apt15440-fig-0001){ref-type="fig"}). Model performance in terms of discriminative ability was described with the Harrell\'s concordance statistic (C‐statistic), which varies between 0.5 (a non‐informative model) and 1.0 (a perfect model). The coefficients were used to calculate the probability of developing worrisome features or high‐risk stigmata within three years and within 5 years, which is presented in a score chart. We used [spss]{.smallcaps} Statistics 22 (IBM Corporation, Armonk, New York, USA) and R Software version 3.3.5 (R foundation for statistical computing, Vienna, Austria) for the statistical analysis.

3. RESULTS {#apt15440-sec-0012}
==========

3.1. Participants and clinical outcome {#apt15440-sec-0013}
--------------------------------------

We included 875 patients. The mean age was 66 (SD 11.2) years, 37% (321) were male, 74% (648) Caucasian, and the mean body mass index was 27 (SD 4.9). At baseline, multifocal cysts were observed in 335 (38%) patients and the average diameter of the largest cyst was 12 mm (SD 6.4, see Table [1](#apt15440-tbl-0001){ref-type="table"} for all baseline characteristics). After a mean follow‐up of 50 months (SD 28.5, range 12‐157) and a total follow‐up of 3649 person‐years, 116 (13.2%) patients developed one or more worrisome features or high‐risk stigmata. Table [2](#apt15440-tbl-0002){ref-type="table"} shows the baseline characteristics according to outcome.

###### 

Baseline patient and cyst characteristics

                                          Erasmus UMC (n = 79)   Columbia UMC (n = 483)   Mayo Clinic Florida (n = 313)
  --------------------------------------- ---------------------- ------------------------ -------------------------------
  Patient characteristics                                                                 
  Age, mean (SD), y                       61 (11.0)              65 (11.9)                68 (9.5)
  Male gender                             20 (25.3)              197 (40.8)               104 (33.2)
  Race                                                                                    
  Caucasian                               64 (81.0)              295 (61.1)               289 (92.3)
  Asian                                   2 (2.5)                20 (4.1)                 3 (1.0)
  Black                                   4 (5.1)                30 (6.2)                 16 (5.1)
  Other                                   4 (5.1)                16 (3.3)                 1 (0.3)
  Unknown                                 5 (6.3)                122 (25.3)               4 (1.3)
  Diabetes mellitus                       10 (12.7)              119 (24.6)               46 (14.7)
  Body mass index, mean (SD)              27 (5.6)               27 (5.0)                 27 (4.8)
  Smoking ever                            27 (34.2)              189 (39.1)               126 (40.3)
  Alcohol ever                            38 (48.1)              198 (41)                 136 (43.5)
  History of acute pancreatitis           9 (11.3)               48 (9.9)                 13 (4.2)
  History of extrapancreatic malignancy   12 (15.2)              195 (40.4)               84 (26.8)
  Family history of PDAC                  10 (12.7)              50 (10.4)                30 (9.6)
  Cyst characteristics                                                                    
  Location dominant cyst                                                                  
  Head                                    52 (65.8)              188 (38.9)               141 (45.0)
  Body                                    22 (27.8)              188 (38.9)               103 (32.9)
  Tail                                    4 (5.1)                106 (21.9)               68 (21.7)
  Multifocality                           43 (54.4)              188 (38.9)               104 (33.2)
  Largest diameter, mean (SD), mm         13 (6.6)               11.5 (6.5)               12 (6.1)

Values presented as n (%) unless otherwise indicated.

Abbreviations: PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation.

John Wiley & Sons, Ltd

###### 

Patient and cyst characteristics separated on study endpoint

                                          Total (N = 875)   No development of WF or HRS (n = 759)   Development of WF or HRS (n = 116)
  --------------------------------------- ----------------- --------------------------------------- ------------------------------------
  Centre                                                                                            
  Erasmus UMC                             79 (9.0)          65 (8.6)                                14 (12.1)
  Columbia UMC                            483 (55.2)        410 (54.0)                              73 (62.9)
  Mayo Clinic Florida                     313 (35.8)        284 (37.4)                              29 (25.0)
  Patient characteristics                                                                           
  Age, mean (SD), y                       66 (11.2)         65 (10.9)                               67 (12.8)
  Male gender                             321 (36.7)        271 (35.7)                              50 (43.1)
  Race                                                                                              
  Caucasian                               648 (74.1)        568 (74.8)                              80 (69.0)
  Asian                                   25 (2.9)          22 (2.9)                                3 (2.6)
  Black                                   50 (5.7)          41 (5.4)                                9 (7.8)
  Other                                   21 (2.3)          18 (2.4)                                3 (2.6)
  Unknown                                 131 (15.0)        110 (14.5)                              21 (18.1)
  Diabetes mellitus                       175 (20.0)        148 (19.5)                              27 (23.3)
  Body mass index, mean (SD)              27 (4.9)          27 (4.9)                                27 (5.3)
  Smoking ever                            342 (39.1)        288 (37.9)                              54 (46.6)
  Alcohol ever                            372 (42.5)        319 (42.0)                              53 (45.7)
  History of acute pancreatitis           70 (8.0)          54 (7.1)                                16 (13.8)
  History of extrapancreatic malignancy   291 (33.3)        246 (32.4)                              45 (38.8)
  Family history of PDAC                  90 (10.3)         80 (10.5)                               10 (8.6)
  Cyst characteristics                                                                              
  Location dominant cyst                                                                            
  Head                                    381 (43.5)        329 (43.3)                              52 (44.8)
  Body                                    313 (35.8)        274 (36.1)                              39 (33.6)
  Tail                                    178 (20.3)        153 (20.2)                              25 (21.6)
  Multifocality                           335 (38.3)        280 (36.9)                              55 (47.4)
  Largest diameter, mean (SD), mm         12 (6.4)          11 (6.0)                                17 (6.7)

Values presented as n (%) unless otherwise indicated.

Abbreviations: HRS, high‐risk stigmata; PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation; WF, worrisome feature.

John Wiley & Sons, Ltd

In the group who developed a worrisome feature, surgery was performed on 36 (31%) patients. Pathology showed an invasive carcinoma in three patients, high‐grade dysplasia in six patients, low or moderate grade dysplasia in 22 patients, a neuroendocrine tumour in one patient, and a mucinous cystic neoplasm in four patients. In the group without a worrisome feature during follow‐up, surgery was performed on 20 (2.6%) patients. Reasons for this included the presence of symptoms (other than jaundice or current pancreatitis), minor growth of a cyst smaller than 3 cm, an increased cyst fluid carcinoembryonic antigen level, a pancreatitis episode in the past (but not at the moment of cyst detection), the patient\'s wishes, or a combination of these reasons. In these cases, pathology showed only low or moderate grade dysplasia (18) or a mucinous cystic neoplasm (2). Of the non‐operated patients, none were diagnosed with pancreatic cancer during follow‐up.

3.2. Missing data and model specification {#apt15440-sec-0014}
-----------------------------------------

None of the patients had missing data for the endpoint, age, cyst multifocality, or initial cyst size. There was ≤ 5% missing data for smoking behaviour (4.5%), personal history of diabetes (0.6%), personal history of acute pancreatitis (2.1%), personal history of extrapancreatic malignancy (1.0%), and family history of pancreatic ductal adenocarcinoma (4.3%). For body mass index, data were missing for 200 (23%) patients.

The model with the best fit included cyst size (HR 1.12, 95% CI 1.09‐1.15), cyst multifocality (HR 1.49, 95% CI 1.01‐2.18), ever having smoked (HR 1.40, 95% CI 0.95‐2.04), history of acute pancreatitis (HR 2.07, 95% CI 1.21‐3.55), and history of extrapancreatic malignancy (HR 1.34, 95% CI 0.91‐1.97). The hazard ratios and 95% CI of each predictive variable in both univariable and multivariable analysis are shown in Table [3](#apt15440-tbl-0003){ref-type="table"}.

###### 

Candidate predictors with associated hazard ratios

  Predictor                               Univariable   Final multivariable model          
  --------------------------------------- ------------- --------------------------- ------ -----------
  Age                                     1.01          0.99‐1.03                   NA     NA
  Body mass index                         1.01          0.96‐1.05                   NA     NA
  Smoking, ever                           1.42          0.98‐2.05                   1.40   0.95‐2.04
  History of diabetes mellitus            1.37          0.89‐2.12                   NA     NA
  History of acute pancreatitis           1.76          1.04‐2.99                   2.07   1.21‐3.55
  History of extrapancreatic malignancy   1.21          0.83‐1.76                   1.34   0.91‐1.97
  Cyst multifocality                      1.65          1.14‐2.41                   1.49   1.01‐2.18
  Largest cyst diameter, per mm           1.12          1.09‐1.15                   1.12   1.09‐1.15

Abbreviations: CI, confidence interval; HR, hazard ratio; NA, not applicable, was not included in the model with the best fit.

John Wiley & Sons, Ltd

3.3. Model performance {#apt15440-sec-0015}
----------------------

Bootstrap resampling showed limited optimism in the C‐statistic of 0.02. In the internal‐external validation, model performance varied between the three subcohorts. The model showed the best discriminative ability in the cohorts of Mayo Clinic Florida (C‐statistic 0.72, 95% CI 0.61‐0.84) and Columbia UMC (C‐statistic 0.71, 95% CI 0.66‐0.80). The performance within the Erasmus UMC cohort was 0.64 (95% CI 0.57‐0.88).

3.4. Score chart and example {#apt15440-sec-0016}
----------------------------

The Dutch‐American Risk stratification Tool (DART‐1) visualises the estimated 3‐year and 5‐year risk of developing one or more worrisome features or high‐risk stigmata for all possible predictor combinations (Figure [2](#apt15440-fig-0002){ref-type="fig"}A,B). A web‐based application has been developed and is available at <https://rtools.mayo.edu/DART/> (Figure [3](#apt15440-fig-0003){ref-type="fig"}). When using the DART‐1, a patient with a unifocal cyst smaller than 1 cm, without a history of acute pancreatitis, extrapancreatic malignancy or smoking, has an estimated 3‐year risk of ≤ 2% and 5‐year risk of ≤ 5% to develop one or more worrisome features or high‐risk stigmata.

![The Dutch‐American Risk stratification Tool (DART‐1) to identify side branch intraductal papillary mucinous neoplasms (SB‐IPMN) at low probability (%) of developing one or more worrisome features or high‐risk stigmata within 3 y (A) or within 5 y (B)](APT-50-789-g002){#apt15440-fig-0002}

![Web‐based application of the Dutch‐American Risk stratification Tool (DART‐1) with an example patient with low probability of developing one or more worrisome features or high‐risk stigmata. The application can be found at <https://rtools.mayo.edu/DART/>](APT-50-789-g003){#apt15440-fig-0003}

4. DISCUSSION {#apt15440-sec-0017}
=============

In this international multicentre study, we describe the development of DART‐1, the first version of a prediction model that does not focus on identifying IPMNs at high risk of malignancy, but on those at low risk instead. It is based on patient and cyst characteristics that can be assessed at the time of diagnosis, and predicts the 3‐year and 5‐year risk of developing worrisome features or high‐risk stigmata as defined by the 2012 international Fukuoka guidelines. Such a model is important, as pancreatic cysts are diagnosed with increasing frequency and yearly imaging is generally recommended, even though the majority of lesions are at low risk of malignant progression. Using a stratifying tool, clinicians can make evidence‐based risk estimations for progression in individual patients and identify those at lowest risk. The ultimate goal would be to decrease the burden of surveillance on patients, but also on health care resources by either optimising surveillance intervals or, in selected cases, discontinue surveillance.

In our cohort, multivariable analysis resulted in five predictors for progression: cyst size, cyst multifocality, ever having smoked, history of acute pancreatitis, and history of extrapancreatic malignancy. Cyst size being an independent predictor of progression comes as no surprise, given that a size of 3 centimetres or greater is defined as a worrisome feature[27](#apt15440-bib-0027){ref-type="ref"} and therefore incorporated in our composite endpoint. However, it has been shown in other cohorts that initial cyst size is a predictor of cyst growth,[30](#apt15440-bib-0030){ref-type="ref"}, [31](#apt15440-bib-0031){ref-type="ref"}, [32](#apt15440-bib-0032){ref-type="ref"} development of other worrisome features,[31](#apt15440-bib-0031){ref-type="ref"}, [33](#apt15440-bib-0033){ref-type="ref"} and malignancy.[12](#apt15440-bib-0012){ref-type="ref"} The predictive value of cyst multifocality has been described less often, but is not a new finding. Crippa et al followed 144 patients with SB‐IPMN for 5 years, and found that an increase in the number of lesions was associated with the development of worrisome features or high‐risk stigmata (OR 6, 95% CI 1.7‐20.8).[33](#apt15440-bib-0033){ref-type="ref"} It was also identified as predictor in an earlier analysis of a subset of our cohort.[26](#apt15440-bib-0026){ref-type="ref"} A history of smoking and of acute pancreatitis are well‐established risk factors for pancreatic cancer,[34](#apt15440-bib-0034){ref-type="ref"}, [35](#apt15440-bib-0035){ref-type="ref"}, [36](#apt15440-bib-0036){ref-type="ref"}, [37](#apt15440-bib-0037){ref-type="ref"} but not for the development of worrisome features in IPMN. Some studies suggest smoking accelerates progression of IPMN, and that it predicts invasive IPMN or concomitant pancreatic cancer in resected IPMN, but results are conflicting.[38](#apt15440-bib-0038){ref-type="ref"}, [39](#apt15440-bib-0039){ref-type="ref"}, [40](#apt15440-bib-0040){ref-type="ref"}, [41](#apt15440-bib-0041){ref-type="ref"}

A history of extrapancreatic malignancy has not been described as a predictor for progression in other cohorts. In the previous analysis of a subset of our cohort, a history of any extrapancreatic malignancy was not an independent predictor, but a history of prostate cancer was. This difference is most likely attributable to the difference in sample size. Retrospective studies have reported an increased incidence of extrapancreatic malignancies in patients with IPMN, but prospective studies were unable to confirm this.[8](#apt15440-bib-0008){ref-type="ref"}, [42](#apt15440-bib-0042){ref-type="ref"} Crippa et al did not find an association between extrapancreatic tumors and the development of worrisome features,[33](#apt15440-bib-0033){ref-type="ref"} but because their cohort consisted of 144 patients of which only 26 developed worrisome features or high‐risk stigmata, this may be due to a lack of power. The predictive value of a history of an extrapancreatic malignancy on progression of IPMN has to be confirmed by studies in other cohorts.

Having a history of diabetes was predictive in the univariable analysis but did not contribute significantly to the multivariable model and was therefore omitted from DART‐1. The association between diabetes and pancreatic cancer is well‐known,[43](#apt15440-bib-0043){ref-type="ref"}, [44](#apt15440-bib-0044){ref-type="ref"}, [45](#apt15440-bib-0045){ref-type="ref"}, [46](#apt15440-bib-0046){ref-type="ref"} but the association with IPMN is less established. Some studies have reported an increased risk for patients with diabetes to develop IPMN,[1](#apt15440-bib-0001){ref-type="ref"}, [47](#apt15440-bib-0047){ref-type="ref"} but in another large population‐based study, this association disappeared after correcting for age and body mass index.[2](#apt15440-bib-0002){ref-type="ref"} Morales‐Oyarvide et al showed that in patients with resected IPMN, preoperative diabetes is associated with high‐grade dysplasia and invasive carcinoma,[48](#apt15440-bib-0048){ref-type="ref"} suggesting diabetes has a proliferative effect on the cyst. However, to the best of our knowledge, there have been no studies that demonstrate that diabetes is associated with the development of worrisome features and high‐risk stigmata. Although diabetes did not contribute to the predictive ability of the model in our cohort, it should be included in validation studies and future updates of DART‐1, to further establish its value.

We encountered some minor differences between the subcohorts, the most noticeable being a higher prevalence of diabetes and personal history of extrapancreatic malignancy in the Columbia cohort, and more multifocal cysts in the Erasmus cohort. However, any meaningful differences between the subcohorts were ruled out by the internal‐external validation. In this type of validation, each subcohort is in turn left out from the development set and used as a validation set. The final model is then based on all available data. Such an internal‐external cross‐validation can be used to demonstrate external validity of a prediction model, with the additional advantage that sample size is retained.[49](#apt15440-bib-0049){ref-type="ref"} DART‐1 performed similarly in the total cohort before validation (apparent performance), the Columbia cohort, and the Mayo cohort. The slight decrease in performance within the Erasmus cohort was expected and is attributable to this cohort\'s smaller sample size.

DART‐1 shows promise, but should be interpreted with some caution. Foremost, prediction models are developed to augment, and not replace clinical judgment, and the given risks are estimates that therefore hold some extent of uncertainty. Also, it is crucial that DART‐1 is validated in other cohorts before it is implemented in clinical care. We expect DART‐1 will be highly generalisable because our development set encompasses three centres, each located in a different geographical region, and each collecting patient data in slightly different time periods. Also, our cohort consists of patients without complex cysts, and is therefore likely to be comparable to the patient population in the primary or secondary care setting. Additionally, we observed limited optimism in the C‐statistic and, therefore, a good external performance is likely.

The main limitation of this prediction model is that it uses a composite, surrogate endpoint. Ideally it would predict development of malignancy. However, given the low cancer risk of SB‐IPMNs, it would require extremely large cohorts to reach adequate numbers for statistical modeling. Although we collected one of the largest low‐risk SB‐IPMN cohorts, it did not yield enough pancreatic cancer cases for this purpose, and we are unable to make predictions on the development of malignancy. However, the ultimate objective of DART‐1 is not to identify high‐risk IPMNs, but those unlikely to develop into malignancy. Although it has been shown that worrisome features and high‐risk stigmata accurately stratify for malignancy risk,[50](#apt15440-bib-0050){ref-type="ref"} it is also known that a substantial number of IPMNs with a worrisome feature do not harbor high‐grade dysplasia or invasive carcinoma,[21](#apt15440-bib-0021){ref-type="ref"}, [22](#apt15440-bib-0022){ref-type="ref"}, [23](#apt15440-bib-0023){ref-type="ref"} which is supported by our own results. IPMNs without worrisome features harbour an even lower risk of developing pancreatic cancer, which strengthens the usefulness of DART‐1 as a negative prediction tool that can be used to identify those SB‐IPMNs that require less intense surveillance.

A second limitation is that we have based our endpoint on the 2012 international Fukuoka guidelines,[27](#apt15440-bib-0027){ref-type="ref"} whereas these were revised in 2017.[16](#apt15440-bib-0016){ref-type="ref"} Similar to the European guidelines,[13](#apt15440-bib-0013){ref-type="ref"} the updated version includes elevated serum carbohydrate antigen 19‐9 levels as a worrisome feature, as well as cyst growth. In our cohorts, serum carbohydrate antigen 19‐9 levels and exact cyst growth were not routinely determined and recorded in the past, because they were under surveillance long before guidelines stressed the importance of these parameters. Because previous studies have shown that cysts not necessarily display a linear growth pattern[31](#apt15440-bib-0031){ref-type="ref"}, [32](#apt15440-bib-0032){ref-type="ref"} and that there is a variability in size measurement between imaging modalities[51](#apt15440-bib-0051){ref-type="ref"} and between observers,[52](#apt15440-bib-0052){ref-type="ref"} it was not possible to reliably assess growth rate retrospectively. Therefore, we could not use the updated guidelines, and fast‐growing IPMNs that did not reach 3 cm during the follow‐up period, may have been misidentified as non‐progressors. Now that serum carbohydrate antigen 19‐9 levels and growth rates are routinely determined as per guidelines, it will be possible to include these variables as part of the study endpoint or as predictor in future updates. Another aspect that could not be completely ruled out, is if our dataset contained a bias by right censoring. However, the predictors in the model did not show an association with follow‐up time, limiting the possible influence of this type of bias.

An issue of much debate is whether the risk of malignancy increases over time. Some recent studies have shown that even small SB‐IPMN may evolve into malignancy after 5 or 10 years,[11](#apt15440-bib-0011){ref-type="ref"}, [12](#apt15440-bib-0012){ref-type="ref"}, [33](#apt15440-bib-0033){ref-type="ref"} and that a stable cyst size for 5 years does not preclude future growth.[53](#apt15440-bib-0053){ref-type="ref"} Because our study population has a mean follow‐up of 50 months, we are not yet able to determine these long‐term risks. At this point in time, this precludes us from stopping surveillance altogether, based on DART‐1. Therefore, we do not advocate a complete stop of surveillance, but suggest a reduction of surveillance frequency for the lowest risk SB‐IPMNs, the ideal cut‐off for which requires further calculation in external cohorts. It is essential to update DART‐1 based on long‐term, prospective data. Additional predictors should be explored, such as diabetes, glycated haemoglobin or serum fasting glucose, serum carbohydrate antigen 19‐9 level, or other promising biomarkers. It may also be of interest to objectify smoking exposure, that is, using pack years as a predictor rather than a history of smoking. It is also conceivable that current smokers are at higher risk than former smokers. Cyst growth may also be a strong predictor, but including this will render the model unfit for use at the time of cyst diagnosis.

In conclusion, we have developed a prediction model that does not focus on detecting high‐risk IPMNs, but identifies IPMNs at lowest risk of developing worrisome features or high‐risk stigmata instead, by combining variables readily available at the time of cyst diagnosis. Even though DART‐1 is the first version of this type of prediction model, it had a good performance in an internal‐external validation, and high generalisability to other cohorts is expected. After DART‐1 is externally validated by others, it can be used to explore varying surveillance strategies using looser follow‐up policies for IPMNs at lowest risk. This very novel approach of stratifying IPMNs has the potential to protect patients with low‐risk IPMNs from redundant medical interventions, and to reduce costs and the burden for the health care system.
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